| Not Yet Recruiting | Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and NCT07513623 | University of California, San Francisco | Phase 2 |
| Not Yet Recruiting | Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Pro NCT07443501 | Institute of Hematology & Blood Diseases Hospital, China | — |
| Recruiting | Study Evaluating the Efficacy and Safety of Artesunate NCT06853184 | Amivas Inc. | Phase 2 |
| Unknown | Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus In NCT06341686 | Hospital do Rim e Hipertensão | Phase 3 |
| Unknown | Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT NCT06075927 | Peking University People's Hospital | Phase 1 / Phase 2 |
| Unknown | Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil NCT06263218 | Hospital do Rim e Hipertensão | — |
| Completed | Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China NCT05789615 | The First Affiliated Hospital of Soochow University | — |
| Unknown | Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies NCT05656599 | Peking University People's Hospital | — |
| Unknown | Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS NCT06021210 | The First Affiliated Hospital of Soochow University | Phase 2 |
| Completed | Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection NCT04934527 | University Hospital, Bordeaux | Phase 2 |
| Unknown | CMV-TCR-T Cells for Refractory CMV Infection After HSCT NCT05089838 | Xiao-Jun Huang | Phase 1 |
| Unknown | Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Tr NCT04278547 | Hospital Universitari de Bellvitge | Phase 4 |
| Completed | Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA NCT05315882 | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | — |
| Terminated | Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells NCT03798301 | University of Wisconsin, Madison | Phase 1 |
| Recruiting | Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections NCT04832607 | Tobias Feuchtinger | Phase 3 |
| Completed | A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection NCT04017962 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections NCT03159364 | Shenzhen Geno-Immune Medical Institute | Phase 1 / Phase 2 |
| Completed | Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation NCT02985775 | Peking University People's Hospital | Phase 1 / Phase 2 |
| Completed | CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. NCT03067155 | University Hospital, Ghent | Phase 2 |
| Completed | Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent C NCT02136797 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Spe NCT02550639 | ORIOL BESTARD | Phase 4 |
| Unknown | MSC for Treatment of CMV Infection NCT02083731 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Suspended | Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT NCT02988258 | University College, London | Phase 1 |
| Unknown | CMV Modulation of the Immune System in ANCA-associated Vasculitis NCT01633476 | Professor Lorraine Harper | Phase 2 |
| Terminated | Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study NCT02843880 | AdministrateurDRC | — |
| Unknown | Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transpl NCT02779439 | University of Sydney | Phase 1 |
| Completed | CMV Intensive Care Units NCT02324244 | Emilio Bouza | — |
| Completed | Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive Individuals NCT00168259 | The Alfred | — |
| No Longer Available | Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CH NCT01945619 | Baylor College of Medicine | — |